D DBV Technologies SA
D
Cerrado
2.374 -1.58
Resumen
Variación precio
24h
Mínimo
2.352
Máximo
2.402
Ingresos | -2.8M -50M |
|---|---|
Ventas | -200K 700K |
BPA | -0.05 |
Margen de beneficios | -7,200 |
Empleados | 170 |
EBITDA | -1.2M -47M |
Próximas Ganancias | 28 oct 2026 |
|---|
Capitalización Mercado | -64M 768M |
|---|---|
Apertura anterior | 3.95 |
Cierre anterior | 2.374 |
DBV Technologies SA Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
DBV Technologies SA previsión
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de DBV Technologies SA
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.